Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

And treat yourself to stunning views of the Burj Khalifa. This Ramadan, book open-air Turkish iftars and suhoors at ...

Equities research analysts at Leerink Partnrs lowered their FY2025 earnings estimates for shares of Karyopharm Therapeutics ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...